Researchers of this recent study identified various challenges when Artificial intelligence (AI) programs used for dermatologic purposes are applied to skin of color (SOC). They mainly stem from the underrepresentation of SOC in datasets and issues with image quality and standardization.
A national targeted melanoma screening program in Australia is a step closer following the recent release of the ‘Skin Checks for Melanoma in Australia Position Statement’, led by Melanoma Institute Australia in collaboration with expert colleagues from across the country.
Authors of this article summarise results from the ongoing phase 3 CheckMate 76K clinical study published online in Nature Medicine in October 2023. Results from CheckMate 76K support the benefit of using nivolumab as a treatment option for people with stage 2 melanoma post-surgery.
According to this recent study, there is benefit in the use of serious games in combination with Augmented Reality to educate and motivate users to perform skin self-examinations (SSE).
Authors of this recent research discuss the functioning and classification of AI using melanoma as an example to build an understanding of the technology behind AI.
Studies reported in this review offer insight into how circulating biomarkers can have a role in personalized treatments for melanoma patients receiving ICIs therapy, emphasizing the need for rigorous clinical trials to confirm findings and establish standardized procedures.
A new position statement regarding balancing the risks and benefits of sun exposure for Australian adults provides sun exposure advice that explicitly recognises the differing needs of Australia’s diverse population.
Circulating tumor DNA (ctDNA) is a predictive and prognostic biomarker that may allow routine, real-time monitoring of melanoma disease status. Authors of this recent study surveyed 44 US physicians to understand their preferences and practice patterns for biomarker and ctDNA testing in their patients with melanoma. The study concludes that physicians consider ctDNA testing potentially valuable for clinical decision-making but cited concerns that should be addressed.
According to this article, we must weigh the absolute benefits of adjuvant systemic therapy in melanoma as a number needed to treat (NNT) and have agreement within society of what is an acceptable balance of NNT versus number needed to harm (NNH).
The aim of this recent study was to explore the acceptability and feasibility of implementing personalised melanoma risk assessment and tailored patient education and skin surveillance within routine clinical care. The study concludes that it is feasible and acceptable to patients and clinic staff to calculate and deliver personalised melanoma risk information and tailored surveillance as part of routine clinical care within dermatology clinics.